Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure. The bone marrow is the place or factory in the body where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability of the bone marrow to make these cells is decreased. The decreased bone marrow function is the result from abnormalities that develop in the malignant cells which prevent the normal maturation process by which bone marrow cells develop into red blood cells, white blo

Trial Details

NCT ID
NCT05184842
Phase
PHASE2
Sponsor
Montefiore Medical Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • Decitabine
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • The Bronx, New York, United States|40.84985,-73.86641
  • White Plains, New York, United States|41.03399,-73.76291

Key Eligibility Criteria

  • Patient must have a diagnosis of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) or myelodysplastic/myeloproliferative neoplasms (MDS/…
  • Indication for therapy with potential sensitivity to hypomethylating agents (HMA) therapy, defined as prior published evidence of response to HMA
  • Patients must be 18 years of age or older
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →